Dr. Wajeeha Razaq, MD
Claim this profileUniversity of Oklahoma Health Sciences Center
Expert in Breast Cancer
Expert in Cancer
24 reported clinical trials
46 drugs studied
About Wajeeha Razaq, MD
Education:
- Obtained an MD (Doctor of Medicine) from the University of Oklahoma Health Sciences Center.
Experience:
- Specializes in breast cancer care and surgery at the Stephenson Cancer Center, Oklahoma City, as a member of a multidisciplinary team of oncology specialists and surgeons.
Area of expertise
1Breast Cancer
Global LeaderHER2 positive
ER positive
Stage IV
2Cancer
Global LeaderHER2 positive
Stage IV
ER positive
Affiliated Hospitals
Clinical Trials Wajeeha Razaq, MD is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
More about Wajeeha Razaq, MD
Clinical Trial Related1 year of experience running clinical trials · Led 24 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Wajeeha Razaq, MD has experience with
- Paclitaxel
- Pertuzumab
- Fulvestrant
- Trastuzumab
- Pembrolizumab
- Fludeoxyglucose F-18
Breakdown of trials Wajeeha Razaq, MD has run
Breast Cancer
Cancer
Recurrence
HER2-Positive Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Wajeeha Razaq, MD specialize in?
Wajeeha Razaq, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Wajeeha Razaq, MD currently recruiting for clinical trials?
Yes, Wajeeha Razaq, MD is currently recruiting for 15 clinical trials in Oklahoma City Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Wajeeha Razaq, MD has studied deeply?
Yes, Wajeeha Razaq, MD has studied treatments such as Paclitaxel, Pertuzumab, Fulvestrant.
What is the best way to schedule an appointment with Wajeeha Razaq, MD?
Apply for one of the trials that Wajeeha Razaq, MD is conducting.
What is the office address of Wajeeha Razaq, MD?
The office of Wajeeha Razaq, MD is located at: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 United States. This is the address for their practice at the University of Oklahoma Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.